According to our latest study on "Transfection Reagents and Equipment Market Forecast to 2030 -Global Analysis - Modality, Product, Application and End User," the market is expected to grow from US$ 1,170.79 million in 2022 and is expected to reach US$ 2,145.03 million by 2030; it is anticipated to record a CAGR of 7.8% from 2022 to 2030. The report highlights the key factors driving the transfection reagents and equipment market growth and prominent players with their developments in the market.
The expansion of the transfection reagents and equipment market size is attributed to the rising cases of chronic diseases and the surging popularity of cell and gene therapy. Transfection is the process of transferring foreign particles and nucleic acids into cells through chemical, physical, and biological means. Transfection reagents are used to improve the efficacy of genetic experiments performed as a part of substantial research conducted in applied gene therapies. In all transfection experiments, the methods by which compounds are delivered into cells must be carefully chosen. Viral-mediated transfection has demonstrated considerable effectiveness, and the transfected products can induce significant immune responses. However, chemical alternatives have been developed to curb the ill effects associated with the use of viruses in the technique.
Transfection is the complex step in developing a viral vector, including adenovirus, adeno-associated virus, and lentivirus. Transient transfection must also be ramped up as the manufacturing processes are scaled up. Process equipment vendors, drug developers, and raw material suppliers are focusing on collaborations to develop cost-effective, practical, and platformizable solutions for rapidly developing and scaling up viral vector manufacturing processes. With planned material volumes and transfer & mixing times, transfecting cells with multiple plasmids becomes feasible on small scales. Scaling up requires experience in industrializing the transfection step since most companies only have transfection experience at the lab level. However, the volume of cell-culture media and transfection reagents required for scaling up the process to a larger level can be impractical, emphasizing the need for optimization.
Nonetheless, broadening the production scale has become common in recent years with the surging demand for viral vectors. With numerous challenges associated with large-scale transfection processes, the best approach to increase production is reducing the process rather than scaling up the process. This top-down approach allows clear identification of the conditions that will impact the process at the industrial level, such as the volume of transfection complex solution. This approach also facilitates process optimization and decision-making. Developing such approaches to ramp up the small-scale transfection processes is an opportunity to grow the transfection reagents and equipment market.
The transfection reagents and equipment market is segmented by application into biomedical research, protein production, and therapeutic delivery. In 2022, the biomedical research segment held the largest share of the market. Moreover, the same segment is expected to grow at the fastest CAGR from 2022 to 2030. Transfection has emerged as a crucial biomedical research technique due to its ability to manipulate gene expression. Gene transfer has been proposed as a new approach to enhance the effectiveness of anti-tumor drugs in treating intractable or metastatic cancers. The association of gene therapy and drugs (similar therapy) has been reported to increase the antiproliferative effects of classic colorectal, lung, pancreatic, bladder, and breast cancer treatments, among others. Cultivated mammalian cells have become a dominant medium for manufacturing recombinant proteins for clinical applications due to their ability to aid proper protein folding, assembly, and posttranslational modifications. Genetically engineered mammalian cell lines generally secrete biotherapeutics into their culture medium, and they can then be purified to homogeneity and sterilized under well-defined regulated conditions. The development of a process for manufacturing recombinant proteins in mammalian cells follows a well-established process that starts with transferring a recombinant gene with the necessary transcriptional regulatory elements to the cells by transfection. Nucleic acid-based therapeutics such as using messenger RNA (mRNA) as a drug molecule have immense potential in treating chronic diseases, including age-related neurodegenerative diseases. Currently, gene therapies such as siRNA, shRNA, CRISPR/Cas9 system, plasmid DNA, antisense oligonucleotide, and miRNA have shown great potential in biomedical applications. Developing sophisticated drug delivery vehicles is of utmost importance to avoid the degradation of gene therapy components in the body, facilitating their effective delivery to target tissues, cells, and organelles. Viral vectors are the most widely used delivery vehicles for in vivo and in vitro gene therapies due to their high transfection efficiency and stable transgene expression.
Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Merck KGaA, Lonza Group, F.Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Mirus Bio LLC, MaxCyte Inc, and Polyplus-Transfection SA are among the leading companies operating in the global transfection reagents and equipment market.
Companies operating in the transfection reagents and equipment market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the transfection reagents and equipment market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to transfection reagents and equipment growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.
- In August 2023, Mirus Bio launched the RevIT AAV Enhancer. When added to the adeno-associated virus (AAV) production process, the novel enhancer increases AAV titers 2-4 times in suspension 293 cells. It can be combined with Mirus Bio's VirusGEN transfection platform and with polymer-only transfection reagents with minimal process optimization. As evidence of its broad applicability, the RevIT Enhancer has been used to increase titers in all AAV serotypes tested to date, with various cell lines and cell culture media commonly used to produce recombinant AAV.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com